AxoGen (AXGN): Key Points From Non Deal Roadshow - Cantor

Cantor Fitzgerald analyst, Travis Steed, reiterated his Overweight rating on shares of AxoGen, Inc. (NASDAQ: AXGN) after hosting a day of Investor/management meetings with Karen Zaderej, CEO, and Peter Mariani, CFO.

4 Key Points:

1) The analyst expects a strong 3Q and believe AXGN will likely raise full-year revenue guidance with 3Q earnings.

2) Small Marketshare - With a 2% market share, AXGN is just penetrating early adopters, but there is growing interest from the middle-adopter surgeons, and AXGN continues to generate buzz at various industry conferences.

3) AXGN recently increased its market opportunity by ~$200m in oral and maxillofacial (OMF)
surgery from accidental nerve injury resolution and use in a new set of procedures (mandible reconstructions due to benign tumor resection).

4) A new opportunity (breast or joint pain) could be announced as soon as its analyst day on November 20, 2017.

No change to the price target of $18.

For an analyst ratings summary and ratings history on AxoGen, Inc. click here. For more ratings news on AxoGen, Inc. click here.

Shares of AxoGen, Inc. closed at $15.55 yesterday.

You May Also Be Interested In

• Lynx Equity on Sandisk: 'Strong buyer into investor confusion', Raises PT to $2,550
• Charles River Associates (CRAI) Tops Q2 EPS by 1c; Offers Guidance
• MarketWise (MKTW) Misses Q2 EPS by 52c